衞寧健康(300253.SZ)：京東健康及藥明康德擬入股衞寧科技
格隆匯 10 月 12日丨衞寧健康(300253.SZ)公佈，公司的參股公司上海金仕達衞寧軟件科技有限公司(“衞寧科技”、“標的公司”)為進一步優化股東結構，壯大資本實力，大力發展商保/醫保智能風控和數據等業務，經各方友好協商，衞寧科技擬通過股權轉讓及增資擴股的方式引入新股東宿遷京東天寧健康科技有限公司(“京東健康”)、無錫藥明康德一期投資企業(有限合夥)(“藥明康德”)。
參考衞寧科技目前的經營情況以及未來的發展及盈利能力，並綜合考慮衞寧科技上一輪融資投後估值(人民幣14億元)、此次股權轉讓及增資相結合等相關因素，經各方友好協商一致確認此次交易價格，即：京東健康以投前估值人民幣18億元受讓趙蒙海持有的部分股權(附帶特定約束條款)及增資，藥明康德以投前估值人民幣16.2億元受讓衞寧健康持有的部分股權(不附帶特定約束條款)及以投前估值人民幣18億元增資。
京東健康擬以人民幣1億元受讓趙蒙海持有的標的公司註冊資本人民幣337.0372萬元，獲得標的公司此次股權轉讓後5.56%的股權(按充分稀釋基礎計算)。在滿足交割和付款條件後，京東健康將分二筆支付受讓價款。
藥明康德擬以人民幣5000萬元受讓衞寧健康持有的標的公司註冊資本人民幣187.2429萬元，獲得標的公司此次股權轉讓後3.09%的股權(按充分稀釋基礎計算)。在滿足交割和付款條件後，藥明康德將一次性支付受讓價款。
京東健康擬以人民幣5000萬元對衞寧科技增資，其中人民幣168.5186萬元計入註冊資本，人民幣4831.4814萬元計入資本公積；藥明康德擬以人民幣9444.4444萬元對衞寧科技增資，其中人民幣318.3129萬元計入註冊資本，人民幣9126.1315萬元計入資本公積。此次增資完成後，京東將取得此次增資交割後標的公司註冊資本2.57%(按充分稀釋基礎計算)的對應股權，藥明康德將取得此次增資交割後標的公司註冊資本4.86%(按充分稀釋基礎計算)的對應股權。
此次交易完成後，標的公司的股權結構如下：
此次交易實施後，公司持有衞寧科技的股權將由42.86%稀釋為36.82%，公司對其長期股權投資仍按權益法核算，預計此次交易對公司税後利潤影響約2435.3萬元(未經審計，具體以註冊會計師審計結果為準)，約佔公司2019年度經審計淨利潤的6.11%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
